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ABSTRACT 26 
Background 27 
Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 28 
24–53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa 29 
is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is 30 
FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) 31 
contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients 32 
with severe COVID-19, and targeting NETs reduces mortality in animal models of acute 33 
respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with 34 
severe COVID-19—acting as a mucolytic and targeting NETs. However, delivery of nebulized 35 
drugs can aerosolize SARS-CoV-2, which causes COVID-19, increasing the infection risk for 36 
staff. Here, we report a single center case series where dornase alfa was administered through 37 
an in-line nebulizer system to minimize risk of virus aerosolization. 38 
 39 
Methods 40 
Demographic, clinical data, and outcomes were collected from the electronic medical records of 41 
five mechanically ventilated patients with COVID-19—including three requiring veno-venous 42 
extracorporeal membrane oxygenation (VV-ECMO)—treated with nebulized in-line endotracheal 43 
dornase alfa co-administered with albuterol (used to increase delivery to the alveoli), between 44 
March 31 and April 24, 2020. Data on tolerability and responses, including longitudinal values 45 
capturing respiratory function and inflammatory status, were analyzed. 46 
 47 
Results 48 
Following nebulized in-line administration of dornase alfa with albuterol, the fraction of inspired 49 
oxygen requirements was reduced for all five patients. All patients remain alive and two patients 50 
have been discharged from the intensive care unit. No drug associated toxicities were identified. 51 
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 52 
Conclusions 53 
The results presented in this case series suggest that dornase alfa will be well-tolerated by 54 
critically ill patients with COVID-19. Clinical trials are required to formally test the dosing, safety, 55 
and efficacy of dornase alfa in COVID-19, and two have recently been registered 56 
(NCT04359654 and NCT04355364). With this case series, we hope to contribute to the 57 
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BACKGROUND 78 
Critically ill patients with coronavirus disease 2019 (COVID-19), caused by the severe acute 79 
respiratory syndrome coronavirus 2 (SARS-CoV-2), progress to hypoxemic and then mixed 80 
respiratory failure, secondary to acute respiratory distress syndrome (ARDS) (1, 2). 81 
Approximately 79–88% of patients admitted to the intensive care unit (ICU) with COVID-19 82 
require intubation and mechanical ventilation, with a mortality of 24–53% (3-6). ARDS in 83 
COVID-19 is characterized by ventilation failure, in part attributable to distally located 84 
mucopurulent secretions. 85 
 86 
Dornase alfa (Pulmozyme®) is recombinant human DNase 1 and a safe mucolytic that is 87 
administered in nebulized form. It is FDA-approved in combination with standard therapies for 88 
patients with cystic fibrosis to improve sputum clearance and pulmonary function (7). It is also 89 
used off-label as a mucolytic in other diseases, including ARDS (8, 9). A mechanism by which 90 
dornase alfa might improve ventilation is by reducing the DNA-mediated viscosity of neutrophil-91 
rich secretions (10). There are multiple sources for the DNA in mucoid sputum, one of which is 92 
neutrophil extracellular traps (NETs). Recently, we collaboratively reported that in the discarded 93 
serum of patients with COVID-19, the levels of NETs were increased and were correlated with 94 
lactate dehydrogenase (LDH), D-dimer, and C-reactive protein (CRP) levels (11). Targeting 95 
NETs reduces mortality in animal models of ARDS (12). Despite recognition that mucolytic 96 
treatment may be beneficial for patients with COVID-19, administration of nebulized 97 
medications, such as dornase alfa, have been limited due to risk of viral aerosolization. If risk of 98 
viral aerosolization can be avoided, dornase alfa may benefit patients with severe COVID-19. by 99 
acting as a mucolytic and by reducing NET levels in the lungs, thereby improving oxygenation 100 
and ventilation. We report the clinical course, safety, and outcomes after nebulized in-line 101 
endotracheal dornase alfa treatment for five intubated and mechanically ventilated patients with 102 
PCR-confirmed COVID-19. 103 
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 104 
METHODS 105 
The Northwell Health institutional review board that focuses on COVID-19 research approved 106 
this case series as minimal-risk research using de-identified data from routine clinical practice. 107 
Data were collected from the enterprise health record (Sunrise Clinical Manager; Allscripts) 108 
reporting database, and included patient demographics, comorbidities, inpatient medications, 109 
laboratory studies, treatment, and outcomes. We further obtained longitudinal values of FiO2 110 
and of the arterial partial pressure of carbon dioxide (PaCO2) as measures of respiratory 111 
function during treatment. FiO2 values of the circuit were reported for those patients who 112 
required veno-venous extracorporeal membrane oxygenation (VV-ECMO). Ferritin, CRP, LDH, 113 
and D-dimer were obtained as measures of systemic disease and inflammation. Not all patients 114 
had laboratory investigations on the same days in relation to the nDA+A treatment. In the 115 
following case synopses, each measurement is therefore followed by the day in relation to the 116 
first day of treatment with nDA+A (e.g. d 2 for the second day of treatment with nDA+A or d -1 117 
for the day before nDA+A treatment was initiated). 118 
 119 
RESULTS 120 
Five patients treated with dornase alfa between March 31, 2020 and April 24, 2020 were 121 
identified. These patients had met the Berlin criteria for ARDS and were treated with ventilator 122 
strategies guided by the ARDSNet protocol at North Shore University Hospital within Northwell 123 
Health (13). They had been treated with dornase alfa because they required high levels of 124 
fraction of inspired oxygen (FiO2) and had elevated ventilation demands. All patients received 125 
the same treatment doses: nebulized dornase alfa (2.5 mg) co-administered twice daily with the 126 
short-acting β2-agonist albuterol (2.5 mg, hereafter abbreviated as nDA+A) to improve delivery 127 
to the alveoli. Of note, β2-adrenoreceptor agonism may also inhibit NET formation by direct 128 
action on neutrophils (14). The treatment was administered with an Aerogen® Solo in-line 129 
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nebulizer to avoid open aerosol generation, which would place staff at risk of exposure to 130 
SARS-CoV-2.  131 
 132 
The patient characteristics are summarized in Table 1. Patients were treated with nDA+A 133 
between 3 to 25 days. The most common characteristics of the patients included obesity 134 
(BMI≥30) and four of the patients had hypertension. Four patients received methylprednisolone 135 
dosed at 1-2mg/kg/day. All patients were treated with full dose or prophylactic dose 136 
anticoagulation for thrombosis. All other medications that were administered during the course 137 
of hospitalization are summarized in Table S1. The clinical course of the five patients treated 138 
with nDA+A is summarized in Figure 1. Figure 2 and 3 display the longitudinal, ventilatory, and 139 
inflammatory markers for each patient. 140 
 141 
Patient 1 is a 56-year-old Hispanic woman who presented in respiratory distress. Her respiratory 142 
status deteriorated over 48 hours, requiring intubation and transfer to the ICU. She was treated 143 
with nDA+A for six days, starting from day 9 of intubation. The FiO2 requirement decreased from 144 
70% (d -1) to 30% (d 6), PaCO2 from 58 (d -1) to 37 mmHg (d 7), ferritin from 1,803 (d -1) to 472 145 
ng/mL (d 6), and D-dimer from 1,619 (d -1) to 563 ng/mL (d 6). Minimal changes were noted in 146 
CRP and LDH. The patient underwent a tracheostomy after 23 days of endotracheal intubation 147 
and remains on an FiO2 of 30% while pending return of mental status. 148 
 149 
Patient 2 is a 34-year-old white man who presented to the hospital in diabetic ketoacidosis 150 
without prior history of diabetes mellitus. He was intubated on admission and initiated on VV-151 
ECMO. He received nDA+A for three days and was de-cannulated after 12 days. The FiO2 152 
requirement decreased from 100% (d 0) to 80% (d 3), CRP from 14.14 (d 0) to 2.41 mg/dL (d 3), 153 
ferritin from 12,281 (d 0) to 5,453 ng/mL (d 3), and D-dimer from 5,210 (d 0) to 2,099 ng/mL (d 154 
3). Minimal changes were noted in PaCO2 and LDH. The patient remains intubated. 155 
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 156 
Patient 3 is a 65-year-old Asian man who was admitted directly to the ICU for respiratory 157 
distress and intubated three days later. Twelve days after intubation, he was started on nine 158 
days of nDA+A treatment. The FiO2 requirement decreased from 50% (d -1) to 40% (d 7), 159 
PaCO2 from 55 (d 0) to 43 mmHg (d 6), and CRP from 22.07 (d 0) to 26.48 mg/dL (d 6). Minimal 160 
changes were noted in ferritin, LDH, and D-dimer. He was extubated one day after the 161 
completion of the nDA+A course. Six days later, he was re-intubated for an additional four days 162 
due to mental status changes and failure to protect his airway. The patient remains extubated in 163 
ICU care. 164 
 165 
Patient 4 is a 31-year-old Hispanic man who was intubated and transferred to the ICU from the 166 
Internal Medicine service two days after presenting with respiratory distress. Nine days after 167 
intubation, he was initiated on VV-ECMO. Five days after cannulation, he was started on the 168 
nDA+A treatment. After nine days, he was de-cannulated and remained intubated for ten days 169 
while continuing the nDA+A treatment. He was then extubated and discharged to the floor. The 170 
FiO2 requirement decreased from 90% (d -1) to 21% (d 7) and LDH from 1,054 (d -1) to 451 U/L 171 
(d 7). Ferritin initially decreased from 1,669 (d -1) to 387 ng/mL (d 7). On day 15 of treatment, 172 
he developed methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and bacteremia. 173 
Ferritin thus increased to 1,619 ng/mL (d 13) prior to decreasing to 555 ng/mL (d 19) with 174 
antibiotic treatment. Minimal changes were noted in PaCO2, CRP, and D-dimer. 175 
 176 
Patient 5 is a 34-year-old black woman who was intubated at an outside hospital, then 177 
transferred to the North Shore University Hospital ICU. Two days later, she was cannulated for 178 
VV-ECMO. She required VV-ECMO for 13 days and was intubated for a total of 29 days. She 179 
was treated with nDA+A for 25 days starting three days following intubation and cannulation. 180 
While on VV-ECMO for the first five days, CytoSorb therapy was applied. She was de-181 
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cannulated after 23 days, extubated after 4 days, and discharged to the floor. The FiO2 182 
requirement fell from 80% (d -1) to 40% (d 7), ferritin from 1,244 (d -1) to 535 ng/mL (d 7), and 183 




At the doses utilized, no nDA+A treatment-associated toxicities were identified. FiO2 188 
requirements decreased for all five patients seven days after nDA+A treatment was initiated. All 189 
patients remain alive at the time of submission of this report, with two patients discharged from 190 
the ICU. We recognize that these FiO2 changes may be independent of the nDA+A treatment. 191 
Clinical trials are therefore required to test the dose range, safety, and efficacy of dornase alfa 192 
in patients with COVID-19 in this setting and possibly earlier in the disease course. Endpoints 193 
should include measurements of the effect on respiratory function as well as on systemic 194 
inflammation, coagulopathy, secondary infections, and the presence of NETs in plasma. Two 195 
such trials were recently registered (NCT04359654 and NCT04355364). 196 
 197 
It is not clear whether nebulized dornase alfa will have any effect on blood NET levels or 198 
systemic inflammation in COVID-19, but a reduction in systemic inflammatory markers has been 199 
reported after use of dornase alfa in patients with cystic fibrosis (7). We did note a reduction in 200 
CRP in two patients (patients 2 and 3) and a reduction in D-dimer in two patients (patients 1 and 201 
2) during nDA+A treatment. LDH was reduced for the patients on VV-ECMO during nDA+A 202 
treatment, and ferritin was reduced in four out of five patients. Due to the small sample size and 203 
the common occurrence of secondary infections in ventilated patients with COVID-19, we are 204 
unable to comment on any potential relationship between nDA+A administration and the risk of 205 
secondary infections.  206 
 207 
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CONCLUSIONS 208 
Nebulized dornase alfa in combination with albuterol may be a safe treatment option for 209 
mechanically ventilated patients with ARDS secondary to COVID-19, including for those on VV-210 
ECMO—a patient population with an urgent, unmet need for effective therapies. 211 
 212 
LIST OF ABBREVIATIONS 213 
ARDS, acute respiratory distress syndrome 214 
BID, bis in die (twice daily) 215 
COVID-19, coronavirus disease 2019 216 
CRP, C-reactive protein 217 
d, day 218 
FiO2, fraction of inspired oxygen 219 
gtt, guttae (intravenous drip) 220 
ICU, intensive care unit 221 
LDH, lactate dehydrogenase 222 
MRSA, methicillin-resistant Staphylococcus aureus 223 
nDA+A, nebulized dornase alfa plus albuterol 224 
NETs, neutrophil extracellular traps 225 
PaCO2, arterial partial pressure of carbon dioxide 226 
SARS-CoV-19, severe acute respiratory syndrome coronavirus 2 227 
VV-ECMO, veno-venous extracorporeal membrane oxygenation 228 
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Disclaimer: The initial characteristics of 5,700 patients from Northwell Health are presented 256 
elsewhere (5). This case series presented in-depth results on the clinical status of five patients 257 
treated with dornase alfa that were not presented in that article. 258 
 259 
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FIGURE LEGENDS:  308 
Figure 1. Overview of the clinical course of five patients treated with nebulized dornase 309 
alfa + albuterol (nDA+A).  310 
 311 
Figure 2. Patient-level data of respiratory function during treatment with nebulized 312 
dornase alfa + albuterol (nDA+A). Values were extracted from the medical records the day 313 
before and up to the seven days after the initiation of treatment. Values are graphed in black for 314 
patients after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not 315 
all markers were measured daily for every patient. FiO2: fraction of inspired oxygen; PaCO2: 316 
partial pressure of carbon dioxide. 317 
 318 
Figure 3. Patient-level data of systemic disease during treatment with nebulized dornase 319 
alfa + albuterol (nDA+A). Values were extracted from the medical records the day before and 320 
up to the seven days after the initiation of treatment. Values are graphed in black for patients 321 
after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not all 322 
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Table 1. Patient data from five patients with COVID-19 who received dornase alfa 335 
with albuterol March–April, 2020. 336 
Patient 1 2 3 4 5 
Clinical Characteristics     
Date of admission 29 March 4 April 16 March 16 March 26 March 
Age 56 34 65 31 34 
Gender F M M M F 
Ethnicity Hispanic White Asian Hispanic Black 
BMI 38 41 32 30 38 
Date of ICU admission 31 March 4 April 16 March 18 March 26 March 
Comorbidities 
          Hypertension 
          Diabetes mellitus, type 2 
          Asthma 
          Hyperlipidemia 
          Migraine 




























Date of ECMO initiation - 4 April - 27 March 28 March 
Date of ECMO cessation - 16 April - 10 April 20 April 
Dornase alfa (DA) + albuterol (A) parameters 
Administration (DA: 2.5 mg, A: 2.5 mg, both twice daily using the Aerogen® Solo nebulizer) 
Date of DA + A initiation 9 April 4 April 31 March 1 April 31 March 
Date of DA + A cessation 14 April 6 April 8 April 19 April 24 April 
Toxicities None None None None None 
Other COVID-19 treatment  
          Methylprednisolone 
          Anakinra 




















          Enoxaparin 
          Argatroban 
          Heparin gtt 
 
40 mg BID 
 
 
120 mg BID 
Yes 
 




100 mg BID 
Yes 
 
120 mg BID 
Yes 
Yes 














*Patients were not on simultaneous anticoagulation therapies. BMI: body mass index; ICU: intensive care unit; 337 
ECMO: extracorporeal membrane oxygenation; BID: bis in die (twice a day); gtt: guttae (intravenous drip); SDVT: 338 
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Supplemental Table 1. Additional medications that dornase alfa+albuterol-treated COVID-346 
19 patients received while in the hospital.  347 
Patient 1 2 3 4 5 
Hospital medications 
          Amiodarone 
          Ampicillin  
          Ascorbic acid 
          Azithromycin 
          Bumetanide 
          Caspofungin 
          Cefepime 
          Ceftriaxone 
          Cisatracurium 
          Dexmedetomidine 
          Dobutamine 
          Esmolol 
          Fentanyl 
          Fluconazole 
          Fosphenytoin 
          Furosemide 
          HCQ/CQ 
          Hydromorphone 
          Insulin 
          IVIG 
          Ketamine 
          Levetiracetam 
          Meropenem 
          Metronidazole 
          Midazolam 
          Milrinone 
          Nicardipine 
          Nitroprusside 
          Norepinephrine 
          Pantoprazole 
          Phenylephrine 
          Propofol 
          Rocuronium 
          Sodium bicarbonate 
          TPN 
          Vancomycin 
          Vasopressin 
          Vecuronium 
































































































































































































Note: All antimicrobials were given at treatment doses. HCQ: hydroxychloroquine; CQ: chloroquine; IVIG: intravenous 348 
immunoglobulin; TPN: total parenteral nutrition 349 
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Figure 3
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